Guidance document on Valproate use in women and girls of childbearing years

Royal College of Physicians of London - RCP
Royal College of Physicians (RCP);Royal College of General Practitioners (RCGP);Royal College of Paediatrics and Child Health (RCPCH)
Publication date:
29 March 2019


Valproate is licensed for use only in the treatment of epilepsy and bipolar disorder. For some women with these conditions, it may be the only drug that controls their condition. This new practical guidance supports doctors and health professionals around valproate use in women and girls of reproductive years. It is based on latest guidance from the MHRA and provides 'pragmatic' advice on situations that arise in clinical practice.